NYSE:USNA
Usana Health Sciences Inc.
Usana Health Sciences Inc.'s revenue grew 8.3% in fiscal 2025 to $925.3M while operating margin fell to 4.0%, its lowest in 10 years. Free cash flow was $8.5M, 0.9% of revenue, and the diluted share count fell 3.1%.Summary generated from Usana Health Sciences Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$925.3M
Revenue growth+8.3%
Revenue, 5-yr CAGR−4.0%
Gross margin78.3%
Operating margin4.0%
Net margin1.2%
ROICn/a
Return on equity2.0%
Debt / equityn/a
Free cash flow$8.5M
FCF margin0.9%
Share count change−3.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,186 | 999 | 921 | 855 | 925 |
| Operating income | 170 | 108 | 93 | 66 | 37 |
| Net income | 117 | 69 | 64 | 42 | 11 |
| Free cash flow | 108 | 94 | 56 | 51 | 9 |
Recent filings
- 8-KEntry into a material agreement
Oct 5, 2026 - 10-QQuarterly report for the period ended Jul 4, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 4Insider transaction report
Jul 27, 2026 - 4Insider transaction report
Jul 27, 2026 - 8-KResults of a shareholder vote
May 20, 2026 - 10-QQuarterly report for the period ended Apr 4, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 5, 2026